The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
- Registry listing
-
ERM Project ID
92305
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part?
Patients with Castrate Resistant Metastatic prostrate cancer.
What is involved for you?
Your doctor will prescribe a hormone tablet for your prostate cancer. There are two similar but slightly different tablets available – abiraterone (Zytiga®), which is taken as two tablets daily (500mg each) and enzalutamide (Xtandi®), which is taken as four capsules daily (40mg each). You will also be asked to continue your regular hormonal injections (androgen deprivation therapy (ADT)) as per your standard treatment. Half of all participants in this trial will take their hormone tablet in the standard fashion. Half will take breaks in treatment when a blood test shows that the tablets have worked to control the cancer. You will see the doctor and study nurse every four weeks for a physical exam and blood test. This blood test will monitor how the treatment is working with a PSA blood test.
